Skip to product information
1 of 1

GeneBio Systems

Recombinant Mouse Erythropoietin/EPO (C-6His)

Recombinant Mouse Erythropoietin/EPO (C-6His)

SKU:PKSM041422

Regular price $788.40 CAD
Regular price Sale price $788.40 CAD
Sale Sold out
Shipping calculated at checkout.

Size: 50μg

Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Cytokines

Abbreviation: Erythropoietin;EPO

Target Synonym: EPO;Epoetin;Erythropoietin

Research Areas:

Conjugation:

Target Species: Mouse

Expression Host: HEK293 Cells

Application: Cell culture

Fusion tag: C-His

UNIProt ID: Q0VED9

Accession: Q0VED9

Background: Erythropoietin (EPO) is a glycoprotein hormone that is principally known for its role in erythropoiesis, where it is responsible for stimulating proliferation and differentiation of erythroid progenitor cells. Erythropoietin is a member of the EPO/TPO family. It is a secreted, glycosylated cytokine composed of four alpha helical bundles. The differentiation of CFU-E (Colony Forming Unit-Erythroid) cells into erythrocytes can only be accomplished in the presence of EPO. Physiological levels of EPO in adult mammals are maintained primarily by the kidneys, whereas levels in fetal or neonatal mammals are maintained by the liver. EPO also can exert various non-hematopoietic activities, including vascularization and proliferation of smooth muscle, neural protection during hypoxia, and stimulation of certain B cells. Genetic variation in erythropoietin is associated with susceptbility to microvascular complications of diabetes type 2. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy.

Concentration:

Activity: Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells The ED50 for this effect is 0.35 ng/ml.

Sequence: Ala27-Arg192

Purity: > 95 % as determined by reducing SDS-PAGE.

Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Reconstitution: Please refer to the printed manual for detailed information.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 19.4 kDa

ObservedMW: 30-40 kDa

View full details